Texas Permanent School Fund grew its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Rating) by 3.9% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 9,371 shares of the specialty pharmaceutical company’s stock after purchasing an additional 350 shares during the quarter. Texas Permanent School Fund’s holdings in ANI Pharmaceuticals were worth $278,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in the company. Comerica Bank lifted its stake in shares of ANI Pharmaceuticals by 31.1% during the 1st quarter. Comerica Bank now owns 11,195 shares of the specialty pharmaceutical company’s stock worth $367,000 after purchasing an additional 2,655 shares during the last quarter. Mutual of America Capital Management LLC lifted its stake in shares of ANI Pharmaceuticals by 23.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 1,833 shares of the specialty pharmaceutical company’s stock worth $52,000 after purchasing an additional 354 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in shares of ANI Pharmaceuticals by 6.7% during the 1st quarter. Commonwealth Equity Services LLC now owns 12,243 shares of the specialty pharmaceutical company’s stock worth $344,000 after purchasing an additional 765 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in shares of ANI Pharmaceuticals during the 1st quarter worth $321,000. Finally, Brown Advisory Inc. lifted its stake in shares of ANI Pharmaceuticals by 23.3% during the 1st quarter. Brown Advisory Inc. now owns 17,634 shares of the specialty pharmaceutical company’s stock worth $496,000 after purchasing an additional 3,333 shares during the last quarter. 56.85% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages recently weighed in on ANIP. StockNews.com began coverage on ANI Pharmaceuticals in a research note on Wednesday, October 12th. They set a “hold” rating for the company. TheStreet upgraded ANI Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, August 17th. HC Wainwright assumed coverage on ANI Pharmaceuticals in a research report on Wednesday, September 7th. They set a “buy” rating and a $50.00 target price on the stock. Finally, Raymond James upped their target price on ANI Pharmaceuticals from $47.00 to $48.00 and gave the company an “outperform” rating in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $49.00.
ANI Pharmaceuticals Trading Up 4.1 %
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products for other companies.
- Get a free copy of the StockNews.com research report on ANI Pharmaceuticals (ANIP)
- After Nixing its 13% Dividend, Is Lumen Technologies Okay To Own?
- Cisco Systems Hopes Restructuring Cuts Costs to Drive Revenue
- The Sell-Side Caps Gains In Dick’s Sporting Goods
- Want to Get a 10% Dividend Yield, Look Here
- Stock-ing Stuffers: 3 Attractive Stocks Trading Around $10
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.